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Monday, February 9, 2015 291anucleotide-gated (CNG) ion channels. CNG channels are cation channels
modulated by cytoplasmic cyclic nucleotides, which play important roles
in sensory signal transduction in eukaryotes. Cell-based assays have accu-
mulated evidence for lipid-modulation of CNG ion channels. To isolate
and systematically study the effect of lipids on CNG channels, we recon-
stituted a model CNG channel into lipid bilayer nanodiscs composed of
phosphocholine, phosphoglycerol and phosphoethanolamine lipids. We char-
acterized these nanodisc preparations using size exclusion chromatography,
electron microscopy and dynamic light scattering to ensure the formation
of nanosized discoidal protein/lipid complexes. The reconstitution of CNG
channels into nanodiscs permits the direct thermodynamic measurement of
cAMP binding to the channel using isothermal titration calorimetry (ITC).
This platform allowed us to probe the binding of cyclic nucleotides to
CNG channels in the presence of different lipids, an important step in under-
standing the molecular mechanism of lipid modulation of CNG channel
gating.Cardiac Muscle Mechanics and Structure I
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Selective alpha7 nicotinic receptor agonists, such as GTS-21, are known to
have neuroprotective and anti-inflammatory actions, but the effect of these
agents on the heart is not known. Therefore, we evaluated the actions
of GTS-21 in isolated atria and isolated hearts from C57BL/6 mice. GTS-21
(1-100 mM) caused a concentration-dependent increase in amplitude of contrac-
tions and decrease in beating rate in isolated atria. Percent changes in rate
and contractile force evoked by 30 mM GTS-21 were 14 5 2 and þ36 5
11, respectively (n ¼ 4). The onset of responses to GTS-21 was slower than
would occur to acetylcholine and norepinephrine, and effects of GTS-21
were not blocked by atropine or atenolol. The impact of GTS-21 on left ventric-
ular function was evaluated next in isolated hearts paced at 400 BPM. Treat-
ment with 30 mM GTS-21 caused significant increases in contractile
function: developed pressure (þ30 5 4%); peak systolic pressure (þ16 5
2%); dP/dtmax (þ31 5 6%). Diastolic pressure was also decreased (60 5
10%) while the rate of relaxation increased (-dP/dtmax, þ36 5 6%) with no
sizable change in coronary perfusion pressure (p < 0.05 for all parameters,
n ¼ 4). Surprisingly, responses to GTS-21 were not affected by a selective
alpha7 antagonist or the nonselective nicotinic antagonist mecamylamine,
and there was no evidence of desensitization. Our data demonstrate that GTS
enhances atrial and ventricular contractility and improves LV relaxation with
a modest decrease in heart rate. GTS-21 cardiac actions occur by a mechanism
that is independent of nicotinic receptors and autonomic nerves. The unique
profile of cardiac effects for GTS-21 suggests its potential use in the setting
of acute heart failure.
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No drugs are capable to prevent phenotype development and adverse cardiac
remodeling in hypertrophic cardiomyopathy (HCM). Ranolazine, a late Naþ
current blocker, reduced arrhythmogenicity and improved relaxation in
cardiomyocytes and trabeculae from HCM patients (Coppini et al., Circula-
tion 2013). Employing a transgenic mouse model carrying the HCM-
associated R92Q mutation in the TNNT2 gene, we previously showed that
acute in vitro treatment with ranolazine is capable to reverse some electro-
mechanical alterations, including the prolonged kinetics of Ca2þ transients,
the higher diastolic [Ca2þ] and the increased frequency of arrhythmogenic
spontaneous activity (Pioner et al., Biophys J 2014, 106, 644a). Here we em-
ployed the same mouse model to assess whether long-term oral treatment
with ranolazine since birth is capable to prevent the HCM phenotype and
the associated myocardial remodeling. We compared the behavior of WT,R92Q-untreated and R92Q-treated 1 year old mice. Echocardiographic mea-
surements showed that the R92Q-treated in vivo hearts lacked the left ven-
tricular hypertrophy, hypercontractility and diastolic dysfunction found in
the R92Q-untreated mice. Gadolinium-contrast magnetic resonance showed
that the intramyocardial fibrosis of the R92Q-untreated hearts was largely
reduced in the treated mice.Both amelioration of cardiomyocyte function
and reduction of extracellular fibrosis may contribute to the positive effect
of the long-term treatment with ranolazine that could represent a candidate
for preventive treatment of phenotype-negative mutation carriers. Mechani-
cal experiments in intact left and right ventricular trabeculae confirmed the
alterations we had previously reported in R92Q-untreated mice compared to
WT and showed that those alterations were mostly reversed in the R92Q-
treated mice. In the R92Q-treated preparations the inotropic response to
isoproterenol was preserved and the occurrence of spontaneous activity
was markedly reduced compared to the untreated trabeculae and was com-
parable to that of WT trabeculae.
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The Ca2þ sensitizer pimobendan is a unique inotropic agent that, compared
with traditional inotropes, improves cardiac contractility with less oxygen
consumption and potentially fewer adverse effects on myocardial remodelling
and arrhythmia. However, clinical trials report contradictory effects of pimo-
bendan in heart failure (HF) patients. We provide mechanistic experimental
evidence of the efficacy of pimobendan using a novel mouse model of pro-
gressive HF.A knock-in mouse model of human genetic dilated cardiomyop-
athy, which shows a clear transition from compensatory to end-stage HF at a
fixed time during growth, was used to evaluate the efficacy of pimobendan
and explore the underlying molecular and cellular mechanisms.Pimobendan
prevented myocardial remodelling in compensated HF and significantly
extended the life span in both compensated and end-stage HF, but dose-
dependently increased the sudden death in end-stage HF. In cardiomyocytes
isolated from end-stage HF mice, pimobendan induced triggered activity
probably due to early or delayed afterdepolarizations via markedly up-
regulated electrogenic sodium/calcium exchanger 1 activation. The L-type
Ca2þ channel blocker verapamil decreased the incidence of triggered activity,
suggesting that this was from overly elevated cytoplasmic Ca2þ through
increased Ca2þ entry by phosphodiesterase 3 inhibition under diminished
sarcoplasmic reticulum Ca2þ reuptake and increased Ca2þ leakage from
sarcoplasmic reticulum in end-stage HF.Pimobendan is beneficial irrespective
of HF stage, but increases sudden cardiac death in end-stage HF with exten-
sive remodelling ofCa2þ handling. Reduction of cytoplasmic Ca2þ elevated
by phosphodiesterase 3 inhibition may decrease the risk of sudden cardiac
death.
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Impaired cGMP-PKG signaling may contribute to cardiomyocyte remodel-
ing and cardiac dysfunction in heart failure with preserved ejection fraction
(HFpEF) patients. The purpose of this study was to assess cardiomyocyte
function and morphology in aortic-banded mini-swine displaying a HFpEF
phenotype following manipulation of cGMP signaling via two mechanisms:
1) driving cGMP synthesis with the DPP4 inhibitor saxagliptin; and 2)
preventing cGMP catabolism via the PDE5 inhibitor tadalafil. We hypothe-
sized that preserving cGMP-PKG signaling would prevent cardiomyocyte
dysfunction and remodeling. Contractile function was measured in enzymat-
ically isolated cardiomyocytes electrically stimulated at three frequencies
(0.25, 0.5, 1.0 Hz)from four groups: control (CON), aortic-banded (AB),
AB saxagliptin-treated (AB-SAX), and AB tadalafil-treated (AB-TAD).
Increased cGMP activity was only observed in AB-TAD animals, however,
neither drug treatment increased PKG activity. A significant pacing-induced
decrease in diastolic sarcomere length was observed in the AB and AB-TAD
groups compared to CON. This finding, indicative of impaired diastolic
relaxation, was prevented by saxagliptin treatment. Shortening amplitude
